Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Diaceutics has released research revealing a critical shift in precision medicine. Despite major advances in biomarker testing, nearly two-thirds of eligible patients with advanced non-small cell lung cancer in the U.S. are still not receiving the most appropriate treatment.

May 01, 2026

Vol.52 No.17

Clinical Roundup

Eating primes immune cells for future responses, UPMC study finds

Eating creates a temporary metabolic state that influences the function of T cells, according to researchers at the University of Pittsburgh.

May 01, 2026

Vol.52 No.17

Drugs & Targets

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

Unfold AI, an AI prostate cancer mapping and clinical decision support platform, is now included in Medicare’s Physician Fee Schedules across the West Coast and Mountain West regions. The regional expansion of Medicare payment for the tool gives urologists and care teams clearer reimbursement pathways in physician office settings, an area that has historically lagged behind hospital outpatient settings for emerging technologies.

May 01, 2026

Vol.52 No.17

Clinical Roundup

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.

April 24, 2026

Vol.52 No.16

Cancer Policy

FDA issues reminder to sponsors: Disclose clinical trial results

FDA issued a stern reminder to medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

The START Center for Cancer Research, a community-based network of clinical trial sites specializing in early-phase oncology trials, announced the appointment of Salwan Al Mutar as director of Clinical Research at START Dallas-Fort Worth.

April 17, 2026

Vol.52 No.15

Alliance prostate cancer trial seeks to reduce toxicity without sacrificing efficacy

YOU MAY BE INTERESTED IN

65% of eligible lung cancer patients do not receive the most appropriate targeted therapies

Eating primes immune cells for future responses, UPMC study finds

Unfold AI’s prostate cancer mapping added to regional CMS Physician Fee Schedule

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

FDA issues reminder to sponsors: Disclose clinical trial results

Salwan Al Mutar named director of clinical research at START Dallas-Fort Worth

Renew today!

Subscriber content

Never miss an issue!

Login